CNM-Au8

Clene wins grant to develop CNM-Au8 for progressive MS

The National Multiple Sclerosis Society has awarded Clene Nanomedicine a grant to advance its treatment candidate CNM-Au8 for people with nonactive, progressive forms of multiple sclerosis (MS). The funding comes from the MS Society’s Fast Forward Program, which supports commercial organizations developing promising new MS therapies,…

ACTRIMS 2023: CNM-Au8 bound for Phase 3 testing after positive data

Treatment with the experimental oral suspension therapy CNM-Au8 led to improvements in measures of vision, cognitive and motor function, and brain health for people with multiple sclerosis (MS), according to data from the proof-of-concept VISIONARY-MS trial. Bolstered by these positive results, Clene Nanomedicine is planning to launch a…

CNM-Au8 preserves white matter in RRMS patients’ brains: Phase 2 trial

Treatment with CNM-Au8, an experimental oral liquid therapy, led to statistically significant improvements in the health of connections between brain regions for people with stable relapsing-remitting multiple sclerosis (RRMS). That’s according to new MRI data from the Phase 2 VISIONARY-MS trial (NCT03536559), which tested CNM-Au8 against a placebo in…

CNM-Au8 Lessens Vision Problems in RRMS Patients in Phase 2 Trial

CNM-Au8, Clene Nanomedicine’s experimental oral therapy, safely and effectively improves vision and neurological function in adults with stable relapsing-remitting multiple sclerosis (RRMS) and disease-related visual impairment. Those are the findings of the VISIONARY-MS Phase 2 clinical trial (NCT03536559), a proof-of-concept study that investigated CNM-Au8 in people with…

VISIONARY-MS Trial of CNM-Au8 to End Early Due to Pandemic

VISIONARY-MS, a Phase 2 clinical trial evaluating the safety and effectiveness of CNM-Au8 in people with relapsing multiple sclerosis (MS) with disease-related visual impairment, will conclude early due to COVID-19 pandemic-related challenges. The release of trial data is expected in the second half of this year, according to…

CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial

Clene’s investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis (RRMS), according to top-line results from the REPAIR-MS trial. This open-label Phase 2 pilot study (NCT03993171), taking place in Texas, is running in parallel with REPAIR-PD, another Phase 2…

#ACTRIMS2018 – Clene Nanomedicine Presents Positive Results for MS Remyelinating Therapy

Clene Nanomedicine says its pre-clinical studies demonstrate the remyelination effects of CNM-Au8, supporting its potential to treat multiple sclerosis (MS) and other demyelinating disorders. Clene presented its data in a session, “Nanocrystalline Gold As a Novel Remyelination Therapeutic for Multiple Sclerosis,” that took place at the third annual Americas…